[CAS NO. 301356-95-6]  79-6 (CID5721353)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [301356-95-6]

Catalog
SLK-S8250
Brand
Selleck
CAS
301356-95-6

DESCRIPTION [301356-95-6]

Overview

MDLMFCD00366372
Molecular Weight457.28
Molecular FormulaC15H9BrN2O6S2
SMILESO=C(O)C(N(C/1=O)C(SC1=C2C(NC3=C\2C=C(Br)C=C3)=O)=S)CC(O)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.1868 mL10.9342 mL21.8684 mL
5 mM0.4374 mL2.1868 mL4.3737 mL
10 mM0.2187 mL1.0934 mL2.1868 mL
50 mM0.0437 mL0.2187 mL0.4374 mL

Description

79-6 (CID5721353) (BCL6 inhibitor) is a inhibitor with Kd value of 138 μM.

Targets

Bcl-6 [3]
138 μM(Kd)

In vitro

Small molecular BCL6 inhibitor 79-6 is a cell-permeable oxindole compound that selectively inhibits the transcriptional repression activity of BCL6 but does not affect BCL6 protein levels. 79-6 binds an aromatic pocket situated in the BTB domain lateral groove, induces disruption of BCL6 transcriptional complexes, reactivation of BCL6 target genes and selective killing of BCL6-dependent DLBCL cells. BCL6 can also interact with MTA3 through its RD2 domain and represses the terminal differentiation. It recruits CtBP through its DBD domain and represses its own expression. 79-6 suppresses invasive ability and colony-forming ability in both of MCF-7 and MDA231 cells. The inhibition of BCL6 with 79-6 enhanced the mRNA expression of E-cadherin in both of MCF-7 and MDA231 cells. 79-6 reverses the functions of BCL6 in the positive regulation of EMT, invasion and transcriptional repression of E-cadherin in breast cancer cells.